Could a simple scan replace biopsies for key cancer marker?

NCT ID NCT06754345

Recruiting now Diagnosis Sponsor: The First Affiliated Hospital of Xiamen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called 68Ga-NK224 that lights up PD-L1, a protein on cancer cells, during a PET/CT scan. Researchers want to see if the scan can accurately measure PD-L1 levels compared to standard tissue biopsy. One hundred adults with various cancers will be scanned, and the results will be compared to their biopsy reports. If it works, this could offer a less invasive way to guide immunotherapy decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-NK224 (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors see PD-L1 levels in tumors without needing a biopsy, guiding better cancer treatment decisions.
What could go wrong: This is an early imaging study with 100 participants. It tests accuracy against biopsy results, so it may not change practice if the scan doesn't match well. No direct treatment benefit for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer disease neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PD-L1 TUMOR

Contacts and locations

Locations

The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.